印度Ranbaxy 
兰伯西（Ranbaxy）实验室有限公司是印度最大的制药公司。它是一个综合性的、研究型的、国际化的制药公司。兰伯西公司生产一系列高质量低价格类普通药品，广受专业护理人员和不同国家和地区病人的信任。兰伯西在全球医药市场的前25名中，名列第23位，在普药企业中排名第八。公司在48个国家设立有分公司，在10个国家建立了生产基地，客户遍及125个国家和地区。

2008年6月，兰伯西公司与日本最大的新药研发公司第一三共株式会社联合组成联盟，创建了一个创新型、普药超级共同体。联盟在全球制药企业中排第15名。这次联盟使兰伯西在全球范围内具有更强的药物分发现和生产能力，预示着有更好的增长和更强大的提高空间。

公司远景规划

2012年，兰伯西将进一步实现其在产品的专有处方与发达市场的实力。公司希望成为普药前五的成员，并在2012年实现全球销售额达50亿美元的计划。

公司财务
兰伯西成立于1961年，1973年财务对外公布。2008年，兰伯西全球销售额达1.682亿美元，年增长率达到了4%。公司在收入和市场中找到了平横点。分别提供了54%和39%销售。在2008年，北美地区成为了公司销售业绩的主要发生地。销售额度高达0.449亿美元，其次在欧洲，销售额为0.33亿美元。此外，在亚洲地区的业务已持续强劲增长，印度大约有0.30亿美元的市场份额，这对于整个市场的支持和品牌建设显得十分重要。

公司战略
兰伯西公司主要关注于普药市场，特别是在仿制药发展的如日中天期间。公司持续关注印度的收并购的机会，新兴市场和发达市场，从而增强其业务和竞争力。随着市场规模的扩大，兰伯西开始涉足到肿瘤、多肽等。这些新增加的领域将进一步延伸产品线。

公司研发
兰伯西致力提供一个可持续、长期竞争优势的重要组成部分的研发能力。公司拥有1200多名研究科学家参与研发工作。
作为上世纪70年代，少数几家以研发起家的兰伯西拥有这全球化的视野。其独一无二的世界级的研发中心是在1994年启用。今天，该公司的多学科的科研活动，Gurgaon的研发中心在印度，住房专用仿制药的研究和创新研究设施。在强大的研发为药物发现和开发D环境反映了该公司的承诺是在仿制药的空间提供价值增值的领导人在其新型给药系统（NDDS）和新化学实体（罗富国）研究能力的基础配方。
新的药物在南新的研究领域包括抗感染，炎症/呼吸，代谢性疾病，肿瘤学，泌尿外科和抗疟疾治疗。

公司员工
该公司的经营理念的基础上提供其利益相关者的价值，不断激发人民的创新，追求卓越并设置新的全球基准。通过其强大的超过12000多元文化劳动力其中包括50个民族的热情的驱使下，兰伯西继续积极推行其使命，致力成为一家基于研究的国际制药公司，实现真正的全球领导地位。（


Ranbaxy Laboratories Limited (Ranbaxy), India's largest pharmaceutical company, is an integrated, research based, international pharmaceutical company, producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy today has a presence in 23 of the top 25 pharmaceutical markets of the world. The Company has a global footprint in 46 countries, world-class manufacturing facilities in 8 countries and serves customers in over 125 countries.

In June 2008, Ranbaxy entered into an alliance with one of the largest Japanese innovator companies, Daiichi Sankyo Company Ltd., to create an innovator and generic pharmaceutical powerhouse. The combined entity now ranks among the top 20 pharmaceutical companies, globally. The transformational deal will place Ranbaxy in a higher growth trajectory and it will emerge stronger in terms of its global reach and in its capabilities in drug development and manufacturing.


Mission

Ranbaxy's mission is ‘Enriching lives globally, with quality and affordable pharmaceuticals.’.

Financials

Ranbaxy was incorporated in 1961 and went public in 1973. For the year 2011, the Company recorded Global Sales of US $ 2.1 Bn. The Company has a balanced mix of revenues from emerging and developed markets that contribute 47% and 46% respectively. In 2011, North America, the Company's largest market contributed sales of US $ 791 Mn, Europe contributing US $ 297 Mn and Asia clocking sales of US $ 503 Mn.

Strategy

Ranbaxy is focused on increasing the momentum in the generics business in its key markets through organic and inorganic growth routes. Growth is well spread across geographies with focus on developed and emerging markets. It is the Company’s constant endeavour to provide a wide basket of generic and innovator products, leveraging the unique Hybrid Business Model with Daiichi Sankyo. The Company will also increasingly focus in high growth potential segments like Vaccines and Biogenerics. These new areas will add significant depth to the existing product pipeline.

R&D

Ranbaxy views its R&D capabilities as a vital component of its business strategy that will provide a sustainable, long-term competitive advantage. The Company has a pool of over 1,200 R&D personnel engaged in path-breaking research.

Ranbaxy is among the few Indian pharmaceutical companies in India to have started its research program in the late 70's, in support of its global ambitions. A first-of-its-kind world class R&D centre was commissioned in 1994. Today, the Company has multi-disciplinary R&D centers at Gurgaon, in India, with dedicated facilities for generics research and innovative research. The R&D environment reflects its commitment to be a leader in the generics space offering value added formulations and development of NDA/ANDAs, based on its Novel Drug Delivery System (NDDS) research capability. Ranbaxy’s first significant international success using the NDDS technology platform came in September 1999, when the Company out-licensed its first once-a-day formulation to a multinational company.

In July 2010, Ranbaxy’s New Drug Discovery Research (NDDR) was transferred to Daiichi Sankyo India Pharma Private Limited as part of the strategy to strengthen the global Research and Development structure of the Daiichi Sankyo Group. While NDDR will now become an integral part of Daiichi Sankyo Life Science Research Center in India, based in Gurgaon, Ranbaxy will continue to independently develop and later commercialise the anti-malarial new drug, Arterolane + PQP, which is currently in Phase III trials. Ranbaxy will also explore the further development of late stage programs developed by NDDR in the last few years, including the development programs in the GSK collaboration. Within Ranbaxy, R&D of Generics will now get a sharper focus, as the Company is increasingly working on more complex and specialist areas.

People

The Company’s business philosophy based on delivering value to its stakeholders constantly inspires its people to innovate, achieve excellence and set new global benchmarks. Driven by the passion of it’s around 14,000 strong multicultural workforce comprising of over 50 nationalities, Ranbaxy continues to aggressively pursue its mission of 'Enriching lives globally, with quality and affordable pharmaceuticals'.